Débora Leite Campos

Mrs. Débora Leite Campos


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DCDébora Leite Campos
Débora Leite Campos
FDFernanda Manaia Demarqui
Fernanda Manaia Demarqui
MSMariana Cristina Solcia
Mariana Cristina Solcia
Paula Carolina de SouzaPaula Carolina de Souza
Paula Carolina de Souza
PMPedro Ivo da Silva Maia
Pedro Ivo da Silva Maia
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence.